Canaccord Genuity Downgrades Thoratec (THOR) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Thoratec® Reports Second Quarter 2015 Results
August 4, 2015 4:02 PM EDTPLEASANTON, Calif., Aug. 4, 2015 /PRNewswire/ --Â Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today reported its financial results for the second quarter and first half of 2015.
"The second quarter continued our trend of improving company and market performance and marked a notable return of revenue growth throughout our business," said D. Keith Grossman, President and Chief Executive Officer. "We were pleased not only with improved market growth, but also with our competitive position, particularly in the U.S.," he... More
